Share Price and Basic Stock Data
Last Updated: November 26, 2025, 6:36 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Adline Chem Lab Ltd operates within the pharmaceuticals industry, currently priced at ₹9.66 with a market capitalization of ₹5.65 Cr. The company has faced significant challenges in generating revenue, as it reported zero sales from March 2023 onwards, continuing a downward trend from ₹0.74 Cr in March 2022. Historical performance showcases a steady decline from ₹13.45 Cr in March 2014 to a staggering ₹0.00 in the latest fiscal year. The company’s expenses, while reduced to ₹0.80 Cr in March 2023 from ₹1.04 Cr in March 2022, have not translated into revenue, highlighting operational inefficiencies. Despite a brief recovery in operating profit margins in prior years, the operating profit has remained negative since March 2020, culminating in a loss of ₹0.80 Cr for the fiscal year ending March 2023. This consistent revenue stagnation raises concerns about the company’s market viability and strategic direction in an increasingly competitive sector.
Profitability and Efficiency Metrics
Adline Chem Lab Ltd’s profitability metrics reveal a challenging financial landscape. The company recorded a net profit loss of ₹4.23 Cr in March 2023, which has been a continuation of negative earnings since March 2020, where it lost ₹3.76 Cr. The operating profit margin (OPM) stood at -40.54% in March 2022 and has not shown improvement since. The interest coverage ratio (ICR) is critically low at -0.27x, indicating that the company is not generating enough earnings to cover its interest obligations, which are minimal at ₹0.16 Cr for March 2025. The return on equity (ROE) is reported at 0.00%, reflecting a complete lack of profitability for equity holders. Moreover, the return on capital employed (ROCE) declined to -74.83% in March 2025, further highlighting the firm’s inefficiency in utilizing its capital effectively. These indicators suggest that Adline Chem Lab Ltd is struggling to achieve operational efficiency and profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Adline Chem Lab Ltd reveals significant weaknesses, particularly in terms of liquidity and leverage. The company has a current ratio of 4.46, indicating a strong liquidity position; however, this is juxtaposed with a negative book value per share of -₹2.55 as of March 2025, suggesting that liabilities exceed assets. Furthermore, the total debt to equity ratio stands at -0.99, indicating a reliance on external financing and raising concerns about financial sustainability. The company’s cash conversion cycle is nonexistent, reflecting a lack of operational activity and efficiency in converting resources into cash flow. The enterprise value as of March 2025 is ₹9.18 Cr, yet with zero revenue generation, the valuation appears inflated relative to operational performance. The financial ratios indicate a precarious financial situation, necessitating a strategic overhaul to restore balance sheet health.
Shareholding Pattern and Investor Confidence
Adline Chem Lab Ltd’s shareholding pattern indicates significant public ownership, with 70.38% of shares held by the public as of March 2025. Promoter holdings have gradually increased to 29.61%, showing a slight rise from 28.24% in previous quarters, which may signal a commitment to the company’s future. However, the absence of significant foreign institutional investors (FIIs) and domestic institutional investors (DIIs) raises questions about broader market confidence in the firm. The number of shareholders has decreased from 18,678 in December 2022 to 18,488 in March 2025, reflecting a potential loss of interest among retail investors. This trend could further exacerbate liquidity challenges in the stock. The high percentage of public holding combined with a declining shareholder base suggests that investor confidence is waning, which may impact future capital raising efforts.
Outlook, Risks, and Final Insight
The outlook for Adline Chem Lab Ltd remains precarious, with continued operational challenges and a lack of revenue generation posing significant risks. The company must address its fundamental issues regarding profitability and operational efficiency to attract investor interest and stabilize its financial health. Key risks include the persistent negative net profit margins, inadequate cash flows, and a reliance on external financing, which could jeopardize its viability in the competitive pharmaceutical sector. The absence of institutional support further complicates its market position. However, if the company can successfully implement strategic changes to enhance revenue generation and operational efficiency, it may regain investor confidence and stabilize its financial footing. The path forward requires a comprehensive strategy focusing on revitalizing sales, improving profitability metrics, and ensuring sustainable growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Adline Chem Lab Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.01 | 0.28 | 0.41 | 0.08 | 0.08 | 0.03 | 0.00 | 0.07 | 0.10 | 0.07 | 0.10 | 0.06 | 0.03 |
| Operating Profit | -0.01 | -0.28 | -0.41 | -0.08 | -0.08 | -0.03 | 0.00 | -0.07 | -0.10 | -0.07 | -0.10 | -0.06 | -0.03 |
| OPM % | |||||||||||||
| Other Income | 0.00 | -3.82 | 0.39 | 0.07 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.00 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Depreciation | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.10 | -4.10 | -0.02 | -0.01 | -0.08 | -0.06 | -0.03 | -0.04 | -0.13 | -0.10 | -0.13 | 0.16 | -0.06 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16.67% | -33.33% | 0.00% | -7.69% | -10.00% | -7.69% | -31.25% | -16.67% |
| Net Profit | -0.10 | -4.10 | -0.02 | -0.01 | -0.08 | -0.05 | -0.02 | -0.04 | -0.13 | -0.09 | -0.12 | 0.21 | -0.05 |
| EPS in Rs | -0.17 | -7.01 | -0.03 | -0.02 | -0.14 | -0.09 | -0.03 | -0.07 | -0.22 | -0.15 | -0.21 | 0.36 | -0.09 |
Last Updated: August 20, 2025, 12:25 am
Below is a detailed analysis of the quarterly data for Adline Chem Lab Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.03 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.03 Cr.. The value appears strong and on an upward trend. It has increased from -0.06 Cr. (Mar 2025) to -0.03 Cr., marking an increase of 0.03 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.25 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.25 Cr..
- For Interest, as of Jun 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.16 Cr. (Mar 2025) to -0.06 Cr., marking a decrease of 0.22 Cr..
- For Tax %, as of Jun 2025, the value is -16.67%. The value appears to be increasing, which may not be favorable. It has increased from -31.25% (Mar 2025) to -16.67%, marking an increase of 14.58%.
- For Net Profit, as of Jun 2025, the value is -0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Mar 2025) to -0.05 Cr., marking a decrease of 0.26 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.09. The value appears to be declining and may need further review. It has decreased from 0.36 (Mar 2025) to -0.09, marking a decrease of 0.45.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:03 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.45 | 15.36 | 16.94 | 17.18 | 8.10 | 5.59 | 6.59 | 6.33 | 0.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 12.43 | 14.42 | 16.50 | 15.97 | 7.23 | 5.01 | 9.91 | 6.56 | 1.04 | 0.80 | 0.18 | 0.30 | 0.24 |
| Operating Profit | 1.02 | 0.94 | 0.44 | 1.21 | 0.87 | 0.58 | -3.32 | -0.23 | -0.30 | -0.80 | -0.18 | -0.30 | -0.24 |
| OPM % | 7.58% | 6.12% | 2.60% | 7.04% | 10.74% | 10.38% | -50.38% | -3.63% | -40.54% | ||||
| Other Income | 0.02 | 0.08 | 0.10 | 0.08 | 0.21 | 0.25 | 0.26 | 0.00 | 1.33 | -3.35 | 0.00 | 0.25 | 0.25 |
| Interest | 0.57 | 0.48 | 0.44 | 0.32 | 0.34 | 0.07 | 0.02 | 0.03 | 0.01 | 0.00 | 0.12 | 0.16 | 0.12 |
| Depreciation | 0.46 | 0.51 | 0.09 | 0.96 | 0.73 | 0.73 | 0.42 | 1.02 | 0.35 | 0.09 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | -3.50 | -1.28 | 0.67 | -4.24 | -0.30 | -0.21 | -0.11 |
| Tax % | 0.00% | 33.33% | 100.00% | 0.00% | 100.00% | 0.00% | 7.43% | 0.00% | -7.46% | 0.00% | -10.00% | -33.33% | |
| Net Profit | 0.01 | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | -3.76 | -1.28 | 0.72 | -4.23 | -0.27 | -0.13 | -0.03 |
| EPS in Rs | 0.02 | 0.03 | 0.02 | 0.02 | 0.00 | 0.05 | -6.43 | -2.19 | 1.23 | -7.23 | -0.46 | -0.22 | -0.06 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | -50.00% | 0.00% | -100.00% | -12633.33% | 65.96% | 156.25% | -687.50% | 93.62% | 51.85% |
| Change in YoY Net Profit Growth (%) | 0.00% | -150.00% | 50.00% | -100.00% | -12533.33% | 12699.29% | 90.29% | -843.75% | 781.12% | -41.77% |
Adline Chem Lab Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 19% |
| TTM: | 79% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 24% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 2:06 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53.46 | 57.74 | 53.87 | 56.30 | 102.74 | 135.81 | 79.20 | 91.11 | 34.53 | |||
| Inventory Days | 109.25 | 77.67 | 46.15 | 55.54 | 181.31 | 832.82 | 81.53 | 46.98 | 197.71 | 0.00 | ||
| Days Payable | 45.42 | 43.12 | 41.39 | 49.24 | 63.34 | 436.97 | 41.89 | 28.91 | 342.19 | |||
| Cash Conversion Cycle | 117.30 | 92.30 | 58.62 | 62.60 | 220.71 | 531.66 | 118.84 | 109.18 | -109.95 | |||
| Working Capital Days | 47.76 | 24.71 | -6.46 | -29.53 | -139.69 | -317.99 | -72.00 | -66.89 | -764.53 | |||
| ROCE % | 4.29% | 3.39% | 2.84% | 2.00% | 1.98% | 0.59% | -40.35% | -23.83% | -10.95% | 5.90% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.21 | -0.25 | -7.24 | 1.23 | -2.19 |
| Diluted EPS (Rs.) | -0.21 | -0.25 | -7.24 | 1.23 | -2.19 |
| Cash EPS (Rs.) | -0.22 | -0.25 | -7.09 | 1.83 | -0.44 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -2.55 | -2.93 | -2.68 | 4.53 | 3.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -2.55 | -2.93 | -2.68 | 4.53 | 3.30 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 1.26 | 10.82 |
| PBDIT / Share (Rs.) | -0.07 | -0.24 | 0.33 | -0.19 | -0.38 |
| PBIT / Share (Rs.) | -0.07 | -0.24 | 0.18 | -0.78 | -2.14 |
| PBT / Share (Rs.) | -0.35 | -0.24 | -7.24 | 1.15 | -2.19 |
| Net Profit / Share (Rs.) | -0.22 | -0.25 | -7.24 | 1.23 | -2.19 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -15.18 | -3.60 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -62.71 | -19.77 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | 91.22 | -20.28 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | 97.44 | -20.28 |
| Return on Networth / Equity (%) | 0.00 | 0.00 | 0.00 | 27.10 | -66.47 |
| Return on Capital Employeed (%) | -74.83 | 10.03 | -8.69 | -15.66 | -53.59 |
| Return On Assets (%) | -175.09 | -347.38 | -6858.26 | 14.72 | -22.77 |
| Long Term Debt / Equity (X) | -0.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | -0.99 | -0.86 | -0.85 | 0.49 | 1.30 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.14 | 0.95 |
| Current Ratio (X) | 4.46 | 0.02 | 0.04 | 0.22 | 0.60 |
| Quick Ratio (X) | 4.46 | 0.02 | 0.04 | 0.09 | 0.48 |
| Interest Coverage Ratio (X) | -0.27 | 0.00 | 0.00 | -15.19 | -6.97 |
| Interest Coverage Ratio (Post Tax) (X) | 0.17 | 0.00 | 0.00 | -56.48 | -38.25 |
| Enterprise Value (Cr.) | 9.18 | 18.23 | 4.43 | 5.11 | 5.64 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 6.93 | 0.89 |
| EV / EBITDA (X) | -204.49 | -124.95 | 22.32 | -45.65 | -24.76 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 5.21 | 0.47 |
| Price / BV (X) | -5.20 | -9.80 | -2.02 | 1.45 | 1.55 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 5.21 | 0.47 |
| EarningsYield | -0.01 | -0.01 | -1.34 | 0.18 | -0.43 |
After reviewing the key financial ratios for Adline Chem Lab Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 5. It has increased from -0.25 (Mar 24) to -0.21, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 5. It has increased from -0.25 (Mar 24) to -0.21, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.22. This value is below the healthy minimum of 3. It has increased from -0.25 (Mar 24) to -0.22, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.55. It has increased from -2.93 (Mar 24) to -2.55, marking an increase of 0.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.55. It has increased from -2.93 (Mar 24) to -2.55, marking an increase of 0.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.07. This value is below the healthy minimum of 2. It has increased from -0.24 (Mar 24) to -0.07, marking an increase of 0.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.07. This value is below the healthy minimum of 0. It has increased from -0.24 (Mar 24) to -0.07, marking an increase of 0.17.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.35. This value is below the healthy minimum of 0. It has decreased from -0.24 (Mar 24) to -0.35, marking a decrease of 0.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.22. This value is below the healthy minimum of 2. It has increased from -0.25 (Mar 24) to -0.22, marking an increase of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is -74.83. This value is below the healthy minimum of 10. It has decreased from 10.03 (Mar 24) to -74.83, marking a decrease of 84.86.
- For Return On Assets (%), as of Mar 25, the value is -175.09. This value is below the healthy minimum of 5. It has increased from -347.38 (Mar 24) to -175.09, marking an increase of 172.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.99. This value is below the healthy minimum of 0.2. It has decreased from 0.00 (Mar 24) to -0.99, marking a decrease of 0.99.
- For Total Debt / Equity (X), as of Mar 25, the value is -0.99. This value is within the healthy range. It has decreased from -0.86 (Mar 24) to -0.99, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 0.02 (Mar 24) to 4.46, marking an increase of 4.44.
- For Quick Ratio (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 2. It has increased from 0.02 (Mar 24) to 4.46, marking an increase of 4.44.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.27. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -0.27, marking a decrease of 0.27.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 3. It has increased from 0.00 (Mar 24) to 0.17, marking an increase of 0.17.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9.18. It has decreased from 18.23 (Mar 24) to 9.18, marking a decrease of 9.05.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -204.49. This value is below the healthy minimum of 5. It has decreased from -124.95 (Mar 24) to -204.49, marking a decrease of 79.54.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is -5.20. This value is below the healthy minimum of 1. It has increased from -9.80 (Mar 24) to -5.20, marking an increase of 4.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Adline Chem Lab Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -74.83% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.99
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 403, Sarthik II, Opp. Rajpath Club, Ahmedabad Gujarat 380054 | secretarial.adlinechemlab@gmail.com http://www.kamronlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sarang Bharatbhai Pathak | Managing Director |
| Mr. Hemant Amrish Parikh | Director |
| Mr. Dhawal Akhilesh Deopura | Director |
| Ms. Shivani Pathak | Director |
| Mr. Vrushank Balkrushna Patel | Additional Director |
| Mr. Nilay Jitendrabhai Vaghasiya | Additional Director |